Sciarra A - Search Results

1

Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: a randomized study.

Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, Gallucci M, Tombolini V, Gentile V, Catalano C. Panebianco V, et al. Among authors: sciarra a. Urol Oncol. 2015 Jan;33(1):17.e1-17.e7. doi: 10.1016/j.urolonc.2014.09.013. Epub 2014 Nov 11. Urol Oncol. 2015. PMID: 25443268 Clinical Trial.

2

Histopathological aspects associated with the diagnosis of benign prostatic hyperplasia: clinical implications.

Sciarra A, Voria G, Mariotti G, Gentile V, Pastore A, Di Silverio F. Sciarra A, et al. Urol Int. 2002;69(4):253-62. doi: 10.1159/000066128. Urol Int. 2002. PMID: 12444279 Review. No abstract available.

3

Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis.

Di Silverio F, Gentile V, De Matteis A, Mariotti G, Giuseppe V, Luigi PA, Sciarra A. Di Silverio F, et al. Among authors: sciarra a. Eur Urol. 2003 Feb;43(2):164-75. doi: 10.1016/s0302-2838(02)00548-1. Eur Urol. 2003. PMID: 12565775

4

Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?

Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, Di Silverio F. Sciarra A, et al. BJU Int. 2003 Mar;91(5):438-45. doi: 10.1046/j.1464-410x.2003.03066.x. BJU Int. 2003. PMID: 12603395 Review. No abstract available.

5

Variation of chromogranin A serum levels after radical retropubic prostatectomy for prostate adenocarcinoma.

Sciarra A, Gentile V, Monti S, Mariotti G, Pastore A, Di Silverio F. Sciarra A, et al. Arch Androl. 2003 Jan-Feb;49(1):39-48. doi: 10.1080/01485010390129160. Arch Androl. 2003. PMID: 12647777 Clinical Trial.

6

Role of radical retropubic prostatectomy in patients with locally advanced prostate cancer: the influence of Gleason score 8-10.

Sciarra A, Gentile V, Voria G, Mariotti G, Seccareccia F, Pastore A, Di Silverio F. Sciarra A, et al. Urol Int. 2003;70(3):186-94. doi: 10.1159/000068777. Urol Int. 2003. PMID: 12660455

7

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.

Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F. Sciarra A, et al. Prostate. 2003 May 15;55(3):168-79. doi: 10.1002/pros.10222. Prostate. 2003. PMID: 12692782 Clinical Trial.

8

Benign prostatic hyperplasia: what about a campaign for prevention?

Di Silverio F, Gentile V, Pastore AL, Voria G, Mariotti G, Sciarra A. Di Silverio F, et al. Among authors: sciarra a. Urol Int. 2004;72(3):179-88. doi: 10.1159/000077112. Urol Int. 2004. PMID: 15084759 Review.

9

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma.

Sciarra A, Bosman C, Monti G, Gentile V, Autran Gomez AM, Ciccariello M, Pastore A, Salvatori G, Fattore F, Di Silverio F. Sciarra A, et al. J Urol. 2004 Nov;172(5 Pt 1):1775-83. doi: 10.1097/01.ju.0000140875.07255.f5. J Urol. 2004. PMID: 15540720 Review.

10

Chromogranin A expression in familial versus sporadic prostate cancer.

Sciarra A, Monti S, Gentile V, Salciccia S, Autran Gòmez AM, Pannunzi LP, Di Silverio F. Sciarra A, et al. Urology. 2005 Nov;66(5):1010-4. doi: 10.1016/j.urology.2005.05.045. Urology. 2005. PMID: 16286114

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

382 results

Search Page

Filters